NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NA
Post# of 196
(Total Views: 84)
Posted On: 12/14/2022 4:07:28 PM
NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Committed to Driving Berubicin Program Forward
CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments, recently announced that the first patient in Europe had been enrolled and dosed in France in the company’s ongoing global trial to evaluate Berubicin for the treatment of recurrent glioblastoma multiforme (“GMB”), an aggressive and incurable form of brain cancer. “Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier (based upon pre-clinical and limited clinical data) and is currently being evaluated in the potentially pivotal study evaluating efficacy and safety for GBM treatment. This study is an adaptive, multicenter, open-label, randomized, and controlled study in adults with recurrent GBM after the failure of standard first-line therapy,” a recent article reads. “CNS Pharmaceuticals has opened 29 clinical sites of the 68 selected across the United States, Italy, France, Spain, and Switzerland… According to CEO John Climaco, the CNS Pharmaceuticals team worked tirelessly to expand its Berubicin clinical trial globally, and the enrollment and dosing of the first patient in France shortly after the opening of the site is a notable accomplishment and confirmation of the team’s commitment to driving the program forward.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments, recently announced that the first patient in Europe had been enrolled and dosed in France in the company’s ongoing global trial to evaluate Berubicin for the treatment of recurrent glioblastoma multiforme (“GMB”), an aggressive and incurable form of brain cancer. “Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier (based upon pre-clinical and limited clinical data) and is currently being evaluated in the potentially pivotal study evaluating efficacy and safety for GBM treatment. This study is an adaptive, multicenter, open-label, randomized, and controlled study in adults with recurrent GBM after the failure of standard first-line therapy,” a recent article reads. “CNS Pharmaceuticals has opened 29 clinical sites of the 68 selected across the United States, Italy, France, Spain, and Switzerland… According to CEO John Climaco, the CNS Pharmaceuticals team worked tirelessly to expand its Berubicin clinical trial globally, and the enrollment and dosing of the first patient in France shortly after the opening of the site is a notable accomplishment and confirmation of the team’s commitment to driving the program forward.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)